0
0

Chapter 16. Fluvoxamine

Elias Aboujaoude, M.D.; Lorrin M. Koran, M.D.
DOI: 10.1176/appi.books.9781585623860.417768

Sections

Excerpt

Fluvoxamine is a member of the selective serotonin reuptake inhibitor (SSRI) family of drugs. Initially manufactured by Duphar Laboratories in the United Kingdom in 1971, fluvoxamine was registered as an antidepressant in Switzerland in 1983, becoming the first drug in the now hugely popular SSRI class to reach the market (Freeman 1991). Since its introduction, fluvoxamine has undergone a wide range of trials to assess its therapeutic potential in depression and across several anxiety disorders, including obsessive-compulsive disorder (OCD). Fluvoxamine has been available in the United States since 1994, when it received U.S. Food and Drug Administration (FDA) approval for the treatment of OCD (Ware 1997). More than 28 million people worldwide have been treated with fluvoxamine (Buchberger and Wagner 2002).

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

FIGURE 16–1. Chemical structure of fluvoxamine.

References

American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition, Revised. Washington, DC, American Psychiatric Association, 1987
 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994
 
Asnis GM, Hameedi FA, Goddard AW, et al: Fluvoxamine in the treatment of panic disorder: a multicenter double-blind, placebo-controlled study in outpatients. Psychiatry Res 103:1–14, 2001
[PubMed]
 
Benfield P, Ward A: Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32:313–334, 1986
[PubMed]
 
Black DW, Monahan P, Gabel J: Fluvoxamine in the treatment of compulsive buying. J Clin Psychiatry 58:159–163, 1997
[PubMed]
 
Black DW, Gabel J, Hansen J, et al: A double-blind comparison of fluvoxamine versus placebo in the treatment of compulsive buying disorder. Ann Clin Psychiatry 12:205–211, 2000
[PubMed]
 
Blanco C, Petkova E, Ibanez A, et al: A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry 14:9–15, 2002
[PubMed]
 
Buchberger R, Wagner W: Fluvoxamine: safety profile in extensive post-marketing surveillance. Pharmacopsychiatry 35:101–108, 2002
[PubMed]
 
Cottraux J, Mollard E, Bouvard M, et al: Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year follow up. Psychiatry Res 49:63–75, 1993
[PubMed]
 
Davidson JR, Weisler RH, Malik M, et al: Fluvoxamine in civilians with posttraumatic stress disorder. J Clin Psychopharmacol 18:93–95, 1998
[PubMed]
 
Davidson J, Yaryura-Tobias J, DuPont R, et al: Fluvoxamine controlled-release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 24:118–125, 2004
[PubMed]
 
De Boer M, Op den Velde W, Falger PJ, et al: Fluvoxamine treatment for chronic PTSD: a pilot study. Psychother Psychosom 57:158–163, 1992
 
DeVane CL: Pharmacokinetics, drug interactions and tolerability of paroxetine and paroxetine CR. Psychopharmacol Bull 37 (suppl 1):29–41, 2003
 
DeVane CL, Gill HS: Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design. J Clin Psychiatry 58 (suppl 5):7–14, 1997
 
Dranovsky A, Hen R: Hippocampal neurogenesis: regulation by stress and antidepressants. Biol Psychiatry 59:1136–1143, 2006
[PubMed]
 
Escalona R, Canive JM, Calais LA, et al: Fluvoxamine treatment in veterans with combat-related post-traumatic stress disorder. Depress Anxiety 15:29–33, 2002
[PubMed]
 
Fichter MM, Kruger R, Rief W, et al: Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology. J Clin Psychopharmacol 16:9–18, 1996
[PubMed]
 
Figgitt DP, McClellan KJ: Fluvoxamine: an updated review of its use in the management of adults with anxiety disorders. Drugs 60:925–954, 2000
[PubMed]
 
Fluvoxamine, in Physicians' Desk Reference, 56th Edition. Montvale, NJ, Medical Economics Company, 2002
 
Fluvoxamine CR (package insert). Palo Alto, CA, Jazz Pharmaceuticals Inc, February 2008. Available at: http://www.luvoxcr.com/LUVOX-CR-PI.pdf. Accessed December 2008.
 
Freeman CP, Trimble MR, Deakin JF, et al: Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 55:301–305, 1994
[PubMed]
 
Freeman CP: Fluvoxamine: clinical trials and clinical use. J Psychiatry Neurosci 16 (2 suppl 1):19–25, 1991
 
Fukuchi T, Kanemoto K: Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: a case-control study. Int Clin Psychopharmacol 17:53–58, 2002
[PubMed]
 
Gentile S: The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf 28:137–152, 2005
[PubMed]
 
Gershon AA, Vishne T, Grunhaus L: Dopamine D2-like receptors and the antidepressant response. Biol Psychiatry 61:145–153, 2007
[PubMed]
 
Haffmans PM, Timmerman L, Hoogduin CA: Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group. Int Clin Psychopharmacol 11:157–164, 1996
[PubMed]
 
Hohagen F, Winkelmann G, Rasche-Ruchle H, et al: Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo: results of a multicentre study. Br J Psychiatry Suppl (35):71–78, 1998
 
Hollander E, DeCaria CM, Mari E, et al: Short-term single-blind fluvoxamine treatment of pathological gambling. Am J Psychiatry 155:1781–1783, 1998
[PubMed]
 
Hollander E, DeCaria CM, Finkell JN, et al: A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry 47:813–817, 2000
[PubMed]
 
Hollander E, Koran LM, Goodman WK, et al: A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry 64:640–647, 2003
[PubMed]
 
Hudson JI, McElroy SL, Raymond NC, et al: Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. Am J Psychiatry 155:1756–1762, 1998
[PubMed]
 
Ishikawa M, Ishiwata K, Ishii K, et al: High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [(11)C]SA4503. Biol Psychiatry 62:878–883, 2007
[PubMed]
 
Kiev A, Feiger A: A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 58:146–152, 1997
[PubMed]
 
Koran LM, McElroy SL, Davidson JR, et al: Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol 16:121–129, 1996
[PubMed]
 
Lapierre YD, Rastoqi RB, Singhal RL: Fluvoxamine influences serotonergic system in the brain: neurochemical evidence. Neuropsychobiology 10:213–216, 1983
[PubMed]
 
Mancama D, Kerwin RW: Role of pharmacogenomics in individualizing treatment with SSRIs. CNS Drugs 17:143–151, 2003
[PubMed]
 
Marmar CR, Schoenfeld F, Weiss DS, et al: Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder. J Clin Psychiatry 57 (suppl 8):66–70, 1996
 
Milanfranchi A, Ravagli S, Lensi P, et al: A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 12:131–136, 1997
[PubMed]
 
Milano W, Siano C, Putrella C, et al: Treatment of bulimia nervosa with fluvoxamine: a randomized controlled trial. Adv Ther 22:278–283, 2005
[PubMed]
 
Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al: SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 23:176–194, 1997
[PubMed]
 
Mundo E, Bianchi L, Bellodi L: Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. J Clin Psychopharmacol 17:267–271, 1997
[PubMed]
 
Mundo E, Maina G, Uslenghi C: Multicenter, double-blind comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 15:69–76, 2000
[PubMed]
 
Mundo E, Rouillon F, Figuera ML, et al: Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Hum Psychopharmacol 16:461–468, 2001
[PubMed]
 
Ninan PT, McElroy SL, Kane CP, et al: Placebo-controlled study of fluvoxamine in the treatment of patients with compulsive buying. J Clin Psychopharmacol 20:362–366, 2000
[PubMed]
 
Otsubo T, Akimoto Y, Yamada H, et al: A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression. Pharmacopsychiatry 38:30–35, 2005
[PubMed]
 
Owens JM, Knight DL, Nemeroff CB: Second generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50:345–350, 2001
[PubMed]
 
Pae CU, Patkar AA: Paroxetine: current status in psychiatry. Expert Rev Neurother 7:107–120, 2007
[PubMed]
 
Palmer KJ, Benfield P: Fluvoxamine: an overview of its pharmacological properties and review of its therapeutic potential in nondepressive disorders. CNS Drugs 1:57–87, 1994
 
Perugi G, Giannotti D, Di Vaio S, et al: Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). Int Clin Psychopharmacol 11:247–254, 1996
[PubMed]
 
Phillips KA, Dwight MM, McElroy SL: Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry 59:165–171, 1998
[PubMed]
 
Phillips KA, McElroy SL, Dwight MM, et al: Delusionality and response to open-label fluvoxamine in body dysmorphic disorder. J Clin Psychiatry 62:87–91, 2001
[PubMed]
 
Price LH, Goodman WK, Charney DS, et al: Treatment of severe obsessive-compulsive disorder with fluvoxamine. Am J Psychiatry 144:1059–1061, 1987
[PubMed]
 
Rao N: The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 46:281–290, 2007
[PubMed]
 
Rapaport M, Coccaro E, Sheline Y, et al: A comparison of fluvoxamine and fluoxetine in the treatment of major depression. J Clin Psychopharmacol 16:373–378, 1996
[PubMed]
 
Ravizza L, Barzega G, Bellino S, et al: Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull 32:167–173, 1996
[PubMed]
 
Riddle MA, Reeve EA, Yaryura-Tobias JA, et al: Fluvoxamine for children and adolescents with obsessive compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 40:222–229, 2001
[PubMed]
 
Rossini D, Serretti A, Franchini L, et al: Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial. J Clin Psychopharmacol 25:471–475, 2005
[PubMed]
 
Ruijten HM, de Bree H, Borst AJ, et al: Fluvoxamine: metabolic fate in animals. Drug Metab Dispos 12:82–92, 1984
[PubMed]
 
Stahl SM: Mechanism of action of selective serotonin reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 51:215–235, 1998
[PubMed]
 
Stanley MA, Breckenridge JK, Swann AC, et al: Fluvoxamine treatment of trichotillomania. J Clin Psychopharmacol 17:278–283, 1997
[PubMed]
 
Stein DJ, Westenberg HG, Yang H et al: Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol 6:317–323, 2003
[PubMed]
 
Stein MB, Fyer AJ, Davidson JR, et al: Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 156:756–760, 1999
[PubMed]
 
Strauss WL, Layton ME, Dager SR: Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy. Am J Psychiatry 155:380–384, 1998
[PubMed]
 
Terra JL, Montgomery SA: Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Int Clin Psychopharmacol 13:55–62, 1998
[PubMed]
 
Tucker P, Smith KL, Marx B, et al: Fluvoxamine reduces physiologic reactivity to trauma scripts in posttraumatic stress disorder. J Clin Psychopharmacol 20:367–372, 2000
[PubMed]
 
Van Harten J: Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 29 (suppl 1):1–9, 1995
 
Van Harten J, Duchier J, Devissaguet JP, et al: Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration. Clin Pharmacokinet 24:177–182, 1993
 
Van Oppen P, Van Balkom AJ, de Haan E, et al: Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up. J Clin Psychiatry 66:1415–1422, 2005
 
Wagner W, Zaborny BA, Gray TE: Fluvoxamine: a review of its safety in world-wide studies. Int Clin Psychopharmacol 9:223–227, 1994
[PubMed]
 
Ware MR: Fluvoxamine: a review of the controlled trials in depression. J Clin Psychiatry 58 (suppl 5):15–23, 1997
 
Westenberg HG, Sadner C: Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract 60:482–491, 2006
[PubMed]
 
Westenberg HG, Stein DJ, Yang H, et al: A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 24:49–55, 2004
[PubMed]
 
Zanardi R, Franchini L, Serretti A, et al: Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. J Clin Psychiatry 61:26–29, 2000
[PubMed]
 
Zohar J, Keegstra H, Barrelet L: Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multicentre, double-blind study. Hum Psychopharmacol 18:113–119, 2003
[PubMed]
 
+

CME Activity

Add a subscription to complete this activity and earn CME credit.
Sample questions:
1.
In regard to its pharmacokinetics, fluvoxamine
2.
Fluvoxamine is a potent inhibitor of the cytochrome P450 (CYP) 1A2 enzyme. A drug whose levels may rise as a result of inhibition of this enzyme by fluvoxamine is
3.
Fluvoxamine also inhibits the cytochrome P450 (CYP) 2C19 enzyme. Which of the following medications is also metabolized by the CYP2C19 isoenzyme?
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
Helping Parents, Youth, and Teachers Understand Medications for Behavioral and Emotional Problems: A Resource Book of Medication Information Handouts, 3rd Edition > Chapter 28.  >
What Your Patients Need to Know About Psychiatric Medications, 2nd Edition > Chapter 21.  >
Topic Collections
Psychiatric News
PubMed Articles
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation